Genomics, Proteomics, & Metabolomics

|2 min read

Roche Expands Mass Spectrometry Menu with CLIA Moderate-Complexity Steroid Assays

The CLIA classification broadens access to advanced testing through a fully automated and standardized workflow on the cobas® i 601 analyzer
|2 min read

Gut Microbiome Connected with Heart Disease Precursor

Using metagenomic sequencing, a new study reports a gut microbiome signature associated with dyslipidemia
|3 min read

Direct-to-Consumer Gut Microbiome Testing Kit Results Vary Between Kits and Manufacturers

The accuracy of gut health tests remains uncertain and no study has systematically evaluated their performance until now
|1 min read

Standardizing Oncology Assays: A Guide to Cell Line-Derived Reference Materials

Identify the limitations of patient tissue controls in genetic testing and examine the verification data supporting cell line-derived standards
Sponsored by
|1 min read

Move Past the Limitations of Synthetic Reference Standards in Cancer Research

A review of cell line-derived reference standards for the investigation and molecular profiling of myeloid malignancies
Sponsored by
|3 min read

FDA Fast-Tracks Ultra-Rare Therapies with Plausible Mechanism Guidance

Framework enables approval of individualized genome editing and RNA-based treatments when traditional trials aren’t feasible
|2 min read

Thermo Fisher Launches All-in-One Kit for Sequential DNA, RNA and Protein Extraction

Integrated solution simplifies multi-layer molecular analysis, advancing precision medicine and translational research
|3 min read

The Future of Companion Diagnostics: A Multi-Omics Revolution

The landscape of companion diagnostics is poised for transformative growth, driven by technological innovation, expanding therapeutic applications, and evolving regulatory support
|2 min read

CAP Highlights Molecular Testing to Clarify Difficult-to-Classify Tumors

CAP authors outline how genomic, transcriptomic, and epigenetic profiling can support pathologists when conventional histology and immunohistochemistry fall short, particularly in cancers of unknown primary
Page 2 of 55